Markets

Tabula Rasa HealthCare Inc. (TRHC), Interview with Dr. Calvin Knowlton, CEO

Watch the CEO Signature Series interview with Dr. Calvin Knowlton, Chief Executive Officer and Chairman of Tabula Rasa HealthCare Inc. (TRHC).

Dr. Calvin Knowlton, CEODr. Calvin Knowlton, CEO

CEO Bio:

Dr. Knowlton has won numerous awards for his leadership in pharmacy, business, and philanthropy in his career of over 30 years, including the 2003 and the 2013 Ernest and Young Entrepreneur of the Year Award, Greater Philadelphia Region, and the 2004 Walter M. Aikman Entrepreneur of the Year Award. He was selected as the Most Influential U.S. Pharmacist in 1997. He has been elected and served as the national President for the American College of Apothecaries, President of the American Pharmacists Association (APhA) for two terms, and President of the American Pharmacists Association Foundation.

Knowlton currently serves on the Board of the Coriell Institute for Medical Research and the Evergreens Continuing Care Retirement Community. He chairs the Board of Coriell Life Sciences, Inc., and serves on the Board of the Cooper Medical School of Rowan University. He serves on the Board (Session) of the First Presbyterian Church in Moorestown NJ and chairs their Long Range Planning Panel. He recently finished his term on the Board of St Christopher’s Hospital for Children in Philadelphia. He is a member of the APhA Pharmacogenomics Task Force, as well as the FDA-recognized National Pharmacogenomics Advisory Group.

Company Description:

Tabula Rasa HealthCare (TRHC) is a leader in providing patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to improve patient outcomes, reduce hospitalizations, lower healthcare costs and manage risk. Medication risk management is TRHC’s lead offering, and its cloud-based software applications provide solutions for a range of payors, providers and other healthcare organizations.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

TRHC

Other Topics

Investing